HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Mental Health · Depression Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Mental Health · Depression Therapeutic Area Assessment

10 signals · 3 insights · 37 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 70%

Evidence

50 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Mental Health · Depression integrates 10 signals, 3 executive insights, and 37 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 23, 2026

    Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT

    The COPE-A treatment showed significantly greater reductions in PTSD symptom severity compared to supportive counseling at 4 months, with effects maintained at 12 months.

    View detail
  2. signalJul 14, 2026

    FDA Supports Development of Psychedelic Drugs for Mental Health

    The FDA is actively supporting the development of psychedelic drugs aimed at treating serious mental health conditions.

    View detail
  3. signalJul 21, 2026

    FDA Grants Abbreviated Approval for Bupropion Hydrochloride by Graviti Pharms

    The FDA has granted abbreviated approval for Bupropion Hydrochloride under application ANDA211020 submitted by Graviti Pharms.

    View detail
  4. signalJul 19, 2026

    Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children

    A multi-center feasibility study is underway to assess the safety and efficacy of the IRE System for treating adenotonsillar hypertrophy in children.

    View detail
  5. regulatoryJul 21, 2026

    FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Application ANDA076003. Sponsor: AMNEAL PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: TRAMADOL HYDROCHLORIDE.

    View detail
  6. regulatoryJul 21, 2026

    FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Application ANDA205177. Sponsor: ANI PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    View detail
  7. regulatoryJul 21, 2026

    FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Application ANDA209021. Sponsor: ASCENT PHARMS INC. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    View detail
  8. regulatoryJul 21, 2026

    FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Application ANDA075968. Sponsor: GRAVITI PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: TRAMADOL HYDROCHLORIDE.

    View detail
  9. insightJul 14, 2026

    FDA's Support for Psychedelic Drugs Signals Competitive Shift in Mental Health Market

    The FDA's support for psychedelic drug development represents a significant shift in the regulatory landscape for mental health treatments. This could lead to rapid market entry for new therapies, necessitating strategic positioning by pharma companies to maintain competitiveness. Regulatory context from FDA (Psychedelic Drugs) supports the near-term read. Assessment grounded in 20 ranked evidence items (15 high-relevance).

    View detail
  10. insightJul 8, 2026

    Digital Therapeutics Gaining Traction in Mental Health Treatment Landscape

    The evaluation of a gamified mobile app for depression underscores the increasing relevance of digital therapeutics in mental health. As traditional treatment modalities face competition from innovative digital solutions, pharma companies must adapt their strategies to incorporate these advancements to maintain market relevance. Regulatory context from FDA (Real-World Evidence Submissions to the Center for Drug Evaluation and Research) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).

    View detail
  11. insightJun 11, 2026

    Innovative Behavioral Interventions for Mental Health in Veterans and Primary Care Settings

    This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population. Assessment grounded in 18 ranked evidence items (7 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 3 risk-calibrated assessments for portfolio review. 37 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA076003. Sponsor: AMNEAL PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: TRAMADOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA205177. Sponsor: ANI PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA209021. Sponsor: ASCENT PHARMS INC. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA075968. Sponsor: GRAVITI PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: TRAMADOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    84%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Bupropion Hydrochloride; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • [ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

    83%

    PMDA regulatory document relevant to this signal.

    Source: PMDA

    View evidence

  • FDA's Support for Psychedelic Drugs Signals Competitive Shift in Mental Health Market

    77%

    The FDA's support for psychedelic drug development represents a significant shift in the regulatory landscape for mental health treatments. This could lead to rapid market entry for new therapies, necessitating strategic positioning by pharma companies to maintain competitiveness. Regulatory context from FDA (Psychedelic Drugs) supports the near-term read. Assessment grounded in 20 ranked evidence items (15 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Digital Therapeutics Gaining Traction in Mental Health Treatment Landscape

    70%

    The evaluation of a gamified mobile app for depression underscores the increasing relevance of digital therapeutics in mental health. As traditional treatment modalities face competition from innovative digital solutions, pharma companies must adapt their strategies to incorporate these advancements to maintain market relevance. Regulatory context from FDA (Real-World Evidence Submissions to the Center for Drug Evaluation and Research) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Innovative Behavioral Interventions for Mental Health in Veterans and Primary Care Settings

    63%

    This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population. Assessment grounded in 18 ranked evidence items (7 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT

    Trial Update

  • FDA Supports Development of Psychedelic Drugs for Mental Health

    Pipeline Update

  • FDA Grants Abbreviated Approval for Bupropion Hydrochloride by Graviti Pharms

    Regulatory Approval

  • Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children

    Trial Update

  • NIMH Study on Adolescent Depression Aims to Enhance Treatment Understanding

    Trial Update

  • Adapting STAIR-NT for Polysubstance Users in Opioid Treatment Programs

    Trial Update

  • Evaluation of Gamified Mobile App for Depression Shows Promise in Reducing Symptoms

    Trial Update

  • Neurovalens Initiates VeNS Trial for Adolescent Anxiety Treatment

    Trial Update

Insights

  • FDA's Support for Psychedelic Drugs Signals Competitive Shift in Mental Health Market

    Mental Health · Psychedelics

  • Digital Therapeutics Gaining Traction in Mental Health Treatment Landscape

    Mental Health · Digital Therapeutics

  • Innovative Behavioral Interventions for Mental Health in Veterans and Primary Care Settings

    Mental Health · Behavioral Interventions

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.